Related Experiment Video

Updated: May 16, 2026

Cellular Toxicity of Nanogenomedicine in MCF-7 Cell Line: MTT assay
19:34

Cellular Toxicity of Nanogenomedicine in MCF-7 Cell Line: MTT assay

Published on: April 3, 2009

Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line

Shatha AbuHammad1, Malek Zihlif

  • 1Department of Pharmacology, Faculty of Medicine, University of Jordan, Amman 11942, Jordan.

Genomics
|December 4, 2012
PubMed

Insights

Doxorubicin resistance in breast cancer involves complex gene expression changes. Key drug metabolism and efflux genes increase, while TOP2A decreases, indicating a multi-factorial resistance process.

Area of Science:

  • Molecular biology
  • Cancer research
  • Pharmacology

Background:

  • Doxorubicin resistance is a significant challenge in cancer chemotherapy.
  • Diverse gene expression profiles contribute to drug resistance across various cancers.

Purpose of the Study:

  • To identify gene expression alterations linked to doxorubicin resistance in MCF7 breast cancer cells.
  • To understand the molecular mechanisms underlying acquired doxorubicin resistance.

Main Methods:

  • Development of a doxorubicin-resistant MCF7 cell line through stepwise selection.
  • Assessment of cell viability using the MTT assay.
  • Analysis of gene expression changes via real-time PCR array.

Main Results:

  • Significant upregulation of phase I/II metabolizing genes, including CYP1A1 (206-fold) and CYP1A2 (96-fold).
  • Profound upregulation of drug efflux pump genes.
  • Strong downregulation of TOP2A (202-fold).
  • Observed alterations in genes involved in cell cycle, apoptosis, and DNA repair.

Conclusions:

  • Doxorubicin resistance in MCF7 cells is a multifactorial process.
  • Altered expression of metabolizing enzymes, efflux pumps, and DNA repair genes contributes to resistance.
  • Findings provide insights into molecular mechanisms of chemotherapy resistance.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer08:20

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer

Published on: May 21, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...